Fri, Aug 22, 2014, 7:53 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • michaelplongo michaelplongo May 12, 2013 4:57 PM Flag

    SGI-110 potential

    From April 26 2013 PR Newswire article titled:
    Eisai's Dacogen Comes Close to Displacing Celgene's Vidaza as Decision Resources' Proprietary Clinical Gold Standard Through 2013 for the Treatment of Myelodysplastic Syndromes

    Two Excerpts:
    A modified dosing schedule of Eisai's Dacogen (decitabine) comes close to displacing Vidaza as Decision Resources' next clinical gold standard but its lack of strong survival data and lower rate of hematological improvement keep it from doing so.
    "Celgene's Vidaza is the only drug for high-risk myelodysplastic syndromes that offers a confirmed benefit in overall survival and the first hypomethylating agent to reach the U.S. and European markets," stated Decision Resources' Analyst Andrew Merron , Ph.D. "Despite this efficacy achievement, surveyed hematologists indicate that there is still considerable unmet need in improving patient survival. Any future drug that proves a significant overall survival benefit over Vidaza and possesses an acceptable level of side effects will gain physician approval and a large portion of sales in the future."
    THIS IS GOOD NEWS FOR SGI-110 IF IT IS INDEED A SUPER DACOGEN

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.